Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Aculys Pharma Poaches Takeda Veteran as New CEO
Aculys Pharma, a Tokyo-based clinical-stage biopharma specializing in neurological disorders, said on April 1 that 30-year industry veteran Hidemasa Tanigaki has been appointed its new CEO, effective March 29. Mr Tanigaki is taking over the reins from Takeshi Takahashi, a…
To read the full story
Related Article
- Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
- Kazunari Tsunaba Steps Down as CEO of Aculys Pharma
November 6, 2023
BUSINESS
- Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
- JCR Outside Director Fauchet Steps Down
September 16, 2026
- MSD Files Oral PCSK9 Inhibitor Enlicitide in Japan
September 15, 2026
- Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
September 15, 2026
- CMIC Names CFO Yoshida as New President
September 15, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…